Abstract
Background: Our objective is to analyze whether the combination of C-reactive protein (CRP), procalcitonin (PCT), presepsin or SCD14-ST and mid-regional pro-adrenomedullin (MR-proADM) measured in the first 24 h from ICU admission allowing a better management of septic patients (diagnostic and prognostic) both in severe sepsis (SS) and septic shock (SSh).
Methods: Cohort study of 388 patients admitted in the ICU during 12 months of whom 142 were controls. Biomarkers were measured through immunoluminometric assays in samples of serum or plasma within the first 24 h after admission. Data were evaluated with non-parametric statistics bivariant, ROC curve analysis for diagnostic evaluation and multivariate analyses for survival analysis.
Results: In the analyzed cohort, 61.8% of patients were males, mean age: 63 years range (18–90) and 67.8% in controls mean age: 63 years, range (39–91). PCT showed the highest area under the curve (AUC) (0.989) as compared with the rest of biomarkers (p<0.01). PCT also enabled the difference between Gram-positive or Gram-negative bacteria to be determined. The AUCs for CRP (0.922) and presepsin (0.948) showed a similar diagnostic value. In cases of SSh, the AUC of presepsin experienced a noticeable increase (p<0.0001). MR-proADM showed a better prognostic value (p=0.00022) particularly in cases of SSh (p=0.00001) increasing along with the APACHE-II score.
Conclusions: PCT, MR-proADM and presepsin are complementary markers that could be of great help in the management of septic patients when they are measured in the first 24 h after ICU admission.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013;369:840–51.10.1056/NEJMra1208623Search in Google Scholar
2. Sepsis alliance. Available from: http://www.sepsisalliance.org. Accessed 24 February, 2014.Search in Google Scholar
3. Daniels R. Surviving the first hours in sepsis: getting the basis right (an intensivist´s perspective). J Antimicrob Chemother 2011;66(Suppl. 2):11–23.10.1093/jac/dkq515Search in Google Scholar
4. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008;34:783–5.10.1007/s00134-008-1040-9Search in Google Scholar
5. Escarce JJ, Kelley MA. Admission source to the medical intensive care unit predicts hospital death independent of APACHE II score. J Am Med Assoc 1990;264:2389–94.10.1001/jama.1990.03450180053028Search in Google Scholar
6. Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. J Am Med Assoc 2001;286:1754–8.10.1001/jama.286.14.1754Search in Google Scholar
7. Vincent JL, Opal SM, Marshall JC. Ten reasons why we should NOT use severity scores as entry criteria for clinical trials or in our treatment decisions. Crit Care Med 2010;38:283–7.10.1097/CCM.0b013e3181b785a2Search in Google Scholar
8. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care 2010;14:R15.10.1186/cc8872Search in Google Scholar
9. Julián Jiménez A. Biomarcadores de infección en urgencias: ¿cuáles pueden sernos útiles? Emergencias 2012;24:343–5.Search in Google Scholar
10. Pizzolato E, Ulla M, Galluzzo C, Lucchiari M, Manetta T, Lupia E, et al. Role of presepsin for the evaluation of sepsis in the emergency department. Clin Chem Lab Med 2014;52:1395–400.10.1515/cclm-2014-0199Search in Google Scholar
11. Hausfater P. Biomarkers and infection in the emergency unit. Med Mal Infect 2014;44:139–45.10.1016/j.medmal.2014.01.002Search in Google Scholar
12. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007;7:210–7.10.1016/S1473-3099(07)70052-XSearch in Google Scholar
13. Nakamura A, Wada H. Efficacy of procalcitonin in the early diagnosis of bacterial infections in a critical care unit. Shock 2009;31:586–91.10.1097/SHK.0b013e31819716faSearch in Google Scholar
14. Vincent JL, Moreno R. Clinical review: scoring systems in the critically ill. Crit Care 2010;14:207.10.1186/cc8204Search in Google Scholar
15. Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med 2003;31:1737–41.10.1097/01.CCM.0000063440.19188.EDSearch in Google Scholar
16. Dorizzi RM, Polati E, Sette P, Ferrari A, Rizzotti P, Luzzani A. Procalcitonin in the diagnosis of inflammation in intensive care units. Clin Biochem 2006;39:1138–43.10.1016/j.clinbiochem.2006.08.011Search in Google Scholar
17. Bereciartua Urbieta E, Mar Medina C, Capelastegui Sáiz A, España Yandiola P, Ajuria Morentín I, Vrotsou K. Proteína C reactiva, procalcitonina y proadrenomedulina en la evolución de neumonías hospitalizadas. Rev Lab Clin 2011;4:23–9.10.1016/j.labcli.2010.11.008Search in Google Scholar
18. Jain S, Sinha S, Sharma SK, Samantaray JC, Aggrawal P, Vikram NK, et al. Procalcitonin as a prognostic marker for sepsis: a prospective observational study. BMC Res Notes 2014;17;7:458.10.1186/1756-0500-7-458Search in Google Scholar
19. Vincent JL, Opal SM, Marshal JC. Sepsis definitions: time for change. Lancet 2013;381:774–5.10.1016/S0140-6736(12)61815-7Search in Google Scholar
20. Layios N, Lambermont B, Canivet J-L, Morimont P, Charles Preiser J, Garweg C. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Crit Care Med 2012;40:2304–9.10.1097/CCM.0b013e318251517aSearch in Google Scholar PubMed
21. Shozushima T, Takahashi G, Matsumoto N, Kojika M, Endo S. Usefulness of presepsin (sCD14-ST) measurements as a marker for diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother 2011;17:764–9.10.1007/s10156-011-0254-xSearch in Google Scholar PubMed
22. Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Mural A, et al. Presepsin as a powerful monitoring tool for the prognosis and treatment of sepsis: a multicenter prospective study. J Infect Chemother 2014;20:30–4.10.1016/j.jiac.2013.07.005Search in Google Scholar PubMed
©2016 by De Gruyter
